UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

Filed b	y the	Registrant ⊠	
Filed b	у а Ра	arty other than the Registrant	
	Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under §240.14a-12		
		Synergy Pharmaceuticals Inc.	
		(Name of Registrant as Specified In Its Charter)	
		(Name of Person(s) Filing Proxy Statement, if other than the Registrant)	
	No fe	Filing Fee (Check the appropriate box): the required. Title of each class of securities to which transaction applies:	
	(2)	Aggregate number of securities to which transaction applies:	
	(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):	
	(4)	Proposed maximum aggregate value of transaction:	
	(5)	Total fee paid:	
	Checl offset	haid previously with preliminary materials. k box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the titing fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the of its filing. Amount Previously Paid:	
	(2)	Form, Schedule or Registration Statement No.:	
	(3)	Filing Party:	
	(4)	Date Filed:	



The Annual Meeting of Stockholders of Synergy Pharmaceuticals Inc. will be held on June 27, 2017, at 9:00 a.m. local time at the Company's offices located at 420 Lexington Avenue, Suite 2012, New York, New York 10170

PROXY STATEMENT AND 2016 ANNUAL REPORT ON FORM 10-K ARE AVAILABLE AT:

http://www.pstvote.com/synergy2017

Dear Stockholder:

The Annual Meeting of Stockholders of Synergy Pharmaceuticals Inc. has been called to consider and act upon the following matters:

- Election of seven Directors;
- Amend the Company's Second Amended and Restated Certificate of Incorporation, as amended, to increase the number of shares of common stock authorized for issuance from 350,000,000 to 400,000,000;
- · Approve the Synergy Pharmaceuticals Inc. 2017 Equity Incentive Plan;
- Ratification of BDO USA, LLP as Synergy's independent registered public accountants for fiscal year ending December 31, 2017.

Our Board of Directors recommends a vote "FOR" all nominees listed in proposal 1 and "FOR" proposals 2, 3 and 4.

You are receiving this communication because you hold shares in the company named above. Complete proxy materials, including the proxy card, are available to you on-line at http://www.pstvote.com/synergy2017 or upon your request by e-mail or first-class mail. We encourage you to access and review all of the important information contained in the proxy materials before voting.

This is not a ballot. You cannot use this notice to vote your shares. You may vote on-line, by mail or in person. If you wish to vote on-line, you will need your "Control Number" (which can be found in the bottom right hand corner of this notice) and the web address, all of which will be included with or on the proxy card located on the Internet website stated above or mailed to you at your request. No other personal information will be required in order to vote in this manner. If you wish to vote by mail, simply print out the proxy card located on the Internet website stated above, mark the proxy card accordingly, sign and return it to us at the address indicated on the proxy card. If you wish to vote in person at the Annual Meeting of Stockholders, simply check the box on the proxy card that you plan to attend. Your proxy card will not be used if you vote in person. Please check the meeting materials for any special requirements for meeting attendance and how to obtain directions to the meeting.

Control Number:

Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting To Be Held on June 27, 2017:

- (1) This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting.
 - (2) The Proxy Statement and 2016 Annual Report on Form 10-K are available at http://www.pstvote.com/ synergy2017.
- (3) If you want to receive a paper or e-mail copy of these documents, you must request one. There is no charge to you for requesting a copy. Please make your request for a copy as instructed below on or before May 24, 2016 to facilitate timely delivery.

To request a paper copy of these items:

- · Call our toll-free number (866) 223-0448; or
- · Visit our website at http://www.pstvote.com/synergy2017; or
- · Send us an e-mail at info@philadelphiastocktransfer.com.

Please clearly identify the items you are requesting; Synergy Pharmaceuticals Inc., and your name along with the Control Number located in the lower right hand corner of this notice and the name and address to which the materials should be mailed.


By Order of the Board of Directors

0000335600_I_RI.0.1.15

*** Exercise Your *Right* to Vote *** mportant Notice Regarding the Availability of Proxy Mate

Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting to Be Held on June 27, 2017

SYNERGY PHARMACEUTICALS INC



Meeting Information

Meeting Type: Annual Meeting For holders as of: April 28, 2017

Date: June 27, 2017 **Time:** 9:00 AM EDT

Location: 420 Lexington Ave
Suite 2012
New York, NY 10170

You are receiving this communication because you hold shares in the above named company.

This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side).

We encourage you to access and review all of the important information contained in the proxy materials before voting.

See the reverse side of this notice to obtain proxy materials and voting instructions.

uctions.

Broadridge Internal Use Only
Job #
Envelope #
Sequence #
of # Sequence

В

Α

R

C

0

D E

You ar shares
This is these overvi-availab

— Before You Vote —

How to Access the Proxy Materials

Proxy Materials Available to VIEW or RECEIVE:

1. Form 10-K 2. Notice & Proxy Statement

How to View Online:

Have the information that is printed in the box marked by the arrow \longrightarrow xxxx xxxx xxxx xxxx xxxx (located on the following page) and visit: www.proxyvote.com

How to Request and Receive a PAPER or E-MAIL Copy:

If you want to receive a paper or e-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the following methods to make your request:

1) BY INTERNET: www.proxyvote.com 2) BY TELEPHONE: 1-800-579-1639

3) BY E-MAIL*: sendmaterial@proxyvote.com

* If requesting materials by e-mail, please send a blank e-mail with the information that is printed in the box marked by the arrow

| XXXX XXXX XXXX XXXX XXXX | (located on the following page) in the subject line.

Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment advisor. Please make the request as instructed above on or before June 06, 2017 to facilitate timely delivery.

— How To Vote —

Please Choose One of the Following Voting Methods

Vote In Person: If you choose to vote these shares in person at the meeting, you must request a "legal proxy." To do so, please follow the instructions at www.proxyvote.com or request a paper copy of the materials, which will contain the appropriate instructions. Many shareholder meetings have attendance requirements including, but not limited to, the possession of an attendance ticket issued by the entity holding the meeting. Please check the meeting materials for any special requirements for meeting attendance.

Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a voting instruction form.

Internal Use Only Voting items

1. Election of Directors

Nominees

- 01 Gary S. Jacob 06 Richard Daly
- 02 Melvin K. Spigelman 03 John P. Brancaccio 04 Thomas H. Adams 05 Alan F. Joslyn 07 Timothy Callahan

The Board of Directors recommends you vote FOR the following proposal(s):

- 2 Proposal to amend the Company's Second Amended and Restated Certificate of Incorporation, as amended, to increase the number of shares of common stock authorized for issuance from 350,000,000 to 400,000,000.
- 3 Proposal to approve the Synergy Pharmaceuticals Inc. 2017 Equity Incentive Plan.
- 4 Proposal to ratify BDO USA, LLP as Synergy's independent registered public accountants for fiscal year ending December 31, 2017.

NOTE: Such other business as may properly come before the meeting or any adjournment thereof.

В A

R

C 0

D

E

→ 0000 0000 0000 0000

Broadridge Internal Use Only xxxxxxxxxx XXXXXXXXXX Voting Instructions

0000335600 4 RI.0.1.15

THIS SPACE RESERVED FOR LANGUAGE PERTAINING TO BANKS AND BROKERS AS REQUIRED BY THE NEW YORK STOCK EXCHANGE

THIS SPACE RESERVED FOR SIGNATURES IF APPLICABLE

Broadridge Internal Use Only Job #

Job # Envelope # Sequence # # of # Sequence #